Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA.

Diabetes. 2018 May 16. pii: db180065. doi: 10.2337/db18-0065. [Epub ahead of print]

PMID:
29769238
2.

Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes.

Naganawa M, Lim K, Nabulsi NB, Lin SF, Labaree D, Ropchan J, Herold KC, Huang Y, Harris P, Ichise M, Cline GW, Carson RE.

Mol Imaging Biol. 2018 Feb 21. doi: 10.1007/s11307-018-1170-6. [Epub ahead of print]

PMID:
29468404
3.

Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-PHNO.

Bini J, Naganawa M, Nabulsi NB, Huang YH, Ropchan J, Lim K, Najafzadeh S, Herold KC, Cline GW, Carson RE.

J Nucl Med. 2018 Jan 25. pii: jnumed.117.197285. doi: 10.2967/jnumed.117.197285. [Epub ahead of print]

PMID:
29371405
4.

MAIT Cells: A Link between Gut Integrity and Type 1 Diabetes.

Gülden E, Palm N, Herold KC.

Cell Metab. 2017 Dec 5;26(6):813-815. doi: 10.1016/j.cmet.2017.11.007.

PMID:
29211981
5.

Microbiota control immune regulation in humanized mice.

Gülden E, Vudattu NK, Deng S, Preston-Hurlburt P, Mamula M, Reed JC, Mohandas S, Herold BC, Torres R, Vieira SM, Lim B, Herazo-Maya JD, Kriegel M, Goodman AL, Cotsapas C, Herold KC.

JCI Insight. 2017 Nov 2;2(21). pii: 91709. doi: 10.1172/jci.insight.91709. [Epub ahead of print]

6.

Oxidative Modifications in Tissue Pathology and Autoimmune Disease.

Yang ML, Doyle HA, Clarke SG, Herold KC, Mamula MJ.

Antioxid Redox Signal. 2017 Dec 11. doi: 10.1089/ars.2017.7382. [Epub ahead of print]

PMID:
29088923
7.

Have we pushed the needle for treatment of Type 1 diabetes?

Naushad N, Perdigoto AL, Rui J, Herold KC.

Curr Opin Immunol. 2017 Dec;49:44-50. doi: 10.1016/j.coi.2017.09.004. Epub 2017 Oct 6. Review.

8.

Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development.

Yu H, Gagliani N, Ishigame H, Huber S, Zhu S, Esplugues E, Herold KC, Wen L, Flavell RA.

Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10443-10448. doi: 10.1073/pnas.1705599114. Epub 2017 Sep 11.

9.

Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.

Long SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, Linsley PS, Nepom GT, Harris KM.

Cell Immunol. 2017 Sep;319:3-9. doi: 10.1016/j.cellimm.2017.07.007. Epub 2017 Aug 18.

10.

Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice.

Ogura M, Deng S, Preston-Hurlburt P, Ogura H, Shailubhai K, Kuhn C, Weiner HL, Herold KC.

Clin Immunol. 2017 Oct;183:240-246. doi: 10.1016/j.clim.2017.07.005. Epub 2017 Jul 21.

PMID:
28739191
11.

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.

Long SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, Ehlers M, Herold KC, Nepom GT, Linsley PS.

Sci Immunol. 2016 Nov;1(5). pii: eaai7793. doi: 10.1126/sciimmunol.aai7793. Epub 2016 Nov 18.

12.

β Cells that Resist Immunological Attack Develop during Progression of Autoimmune Diabetes in NOD Mice.

Rui J, Deng S, Arazi A, Perdigoto AL, Liu Z, Herold KC.

Cell Metab. 2017 Mar 7;25(3):727-738. doi: 10.1016/j.cmet.2017.01.005. Epub 2017 Feb 9.

13.

Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection.

Mesquita PMM, Preston-Hurlburt P, Keller MJ, Vudattu N, Espinoza L, Altrich M, Anastos K, Herold KC, Herold BC.

J Infect Dis. 2017 Feb 15;215(4):614-622. doi: 10.1093/infdis/jiw612.

14.

Unmethylated Insulin DNA Is Elevated After Total Pancreatectomy With Islet Autotransplantation: Assessment of a Novel Beta Cell Marker.

Bellin MD, Clark P, Usmani-Brown S, Dunn TB, Beilman GJ, Chinnakotla S, Pruett TL, Ptacek P, Hering BJ, Wang Z, Gilmore T, Wilhelm JJ, Hodges JS, Moran A, Herold KC.

Am J Transplant. 2017 Apr;17(4):1112-1118. doi: 10.1111/ajt.14054. Epub 2016 Oct 24.

15.

GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.

Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2017 Jan;60(1):43-49. Epub 2016 Oct 4.

16.

The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus.

Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC; Type 1 Diabetes TrialNet Study Group.

J Immunol. 2016 Oct 15;197(8):3076-3085. Epub 2016 Sep 21.

17.

Progress and challenges for treating Type 1 diabetes.

Garyu JW, Meffre E, Cotsapas C, Herold KC.

J Autoimmun. 2016 Jul;71:1-9. doi: 10.1016/j.jaut.2016.04.004. Epub 2016 May 17. Review.

18.

Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes.

Boyle KD, Keyes-Elstein L, Ehlers MR, McNamara J, Rigby MR, Gitelman SE, Weiner LJ, Much KL, Herold KC.

Diabetes Care. 2016 Jun;39(6):e76-8. doi: 10.2337/dc15-2077. Epub 2016 Apr 13. No abstract available.

19.

Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals.

Herrin M, Tate JP, Akgün KM, Butt AA, Crothers K, Freiberg MS, Gibert CL, Leaf DA, Rimland D, Rodriguez-Barradas MC, Ruser CB, Herold KC, Justice AC.

J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):228-36. doi: 10.1097/QAI.0000000000001071.

20.

Life and death of β cells in Type 1 diabetes: A comprehensive review.

Wilcox NS, Rui J, Hebrok M, Herold KC.

J Autoimmun. 2016 Jul;71:51-8. doi: 10.1016/j.jaut.2016.02.001. Epub 2016 Mar 24. Review.

21.

Characterization of Diabetogenic CD8+ T Cells: IMMUNE THERAPY WITH METABOLIC BLOCKADE.

Garyu JW, Uduman M, Stewart A, Rui J, Deng S, Shenson J, Staron MM, Kaech SM, Kleinstein SH, Herold KC.

J Biol Chem. 2016 May 20;291(21):11230-40. doi: 10.1074/jbc.M115.713362. Epub 2016 Mar 18.

22.

Methylation of insulin DNA in response to proinflammatory cytokines during the progression of autoimmune diabetes in NOD mice.

Rui J, Deng S, Lebastchi J, Clark PL, Usmani-Brown S, Herold KC.

Diabetologia. 2016 May;59(5):1021-9. doi: 10.1007/s00125-016-3897-4. Epub 2016 Feb 24.

23.

Inducing and Administering Tregs to Treat Human Disease.

Perdigoto AL, Chatenoud L, Bluestone JA, Herold KC.

Front Immunol. 2016 Jan 22;6:654. doi: 10.3389/fimmu.2015.00654. eCollection 2015. Review.

24.

A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.

Gill RG, Pagni PP, Kupfer T, Wasserfall CH, Deng S, Posgai A, Manenkova Y, Bel Hani A, Straub L, Bernstein P, Atkinson MA, Herold KC, von Herrath M, Staeva T, Ehlers MR, Nepom GT.

Diabetes. 2016 May;65(5):1310-6. doi: 10.2337/db15-0492. Epub 2015 Dec 30.

25.

Rituximab does not reset defective early B cell tolerance checkpoints.

Chamberlain N, Massad C, Oe T, Cantaert T, Herold KC, Meffre E.

J Clin Invest. 2016 Jan;126(1):282-7. doi: 10.1172/JCI83840. Epub 2015 Dec 7.

26.

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q.

Sci Transl Med. 2015 Nov 25;7(315):315ra189. doi: 10.1126/scitranslmed.aad4134.

27.

Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells.

Hernandez AL, Kitz A, Wu C, Lowther DE, Rodriguez DM, Vudattu N, Deng S, Herold KC, Kuchroo VK, Kleinewietfeld M, Hafler DA.

J Clin Invest. 2015 Nov 2;125(11):4212-22. doi: 10.1172/JCI81151. Epub 2015 Oct 20.

28.

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.

Tooley JE, Vudattu N, Choi J, Cotsapas C, Devine L, Raddassi K, Ehlers MR, McNamara JG, Harris KM, Kanaparthi S, Phippard D, Herold KC.

Eur J Immunol. 2016 Jan;46(1):230-41. doi: 10.1002/eji.201545708. Epub 2015 Dec 14.

29.

Endocrinology research-reflecting on the past decade and looking to the next.

Herold KC, Majzoub JA, Melmed S, Pendergrass M, Schlumberger M.

Nat Rev Endocrinol. 2015 Nov;11(11):672-80. doi: 10.1038/nrendo.2015.164. Epub 2015 Oct 13. Review.

PMID:
26460340
30.

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2015 Oct;38(10):1975-85. doi: 10.2337/dc15-1429. Review.

31.

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG.

Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419. Review.

32.

Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy.

Hughes J, Vudattu N, Sznol M, Gettinger S, Kluger H, Lupsa B, Herold KC.

Diabetes Care. 2015 Apr;38(4):e55-7. doi: 10.2337/dc14-2349. No abstract available.

33.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

34.

β cell death and dysfunction during type 1 diabetes development in at-risk individuals.

Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP; Type 1 Diabetes TrialNet Study Group.

J Clin Invest. 2015 Mar 2;125(3):1163-73. doi: 10.1172/JCI78142. Epub 2015 Feb 2.

35.

Thinking bedside at the bench: the NOD mouse model of T1DM.

Reed JC, Herold KC.

Nat Rev Endocrinol. 2015 May;11(5):308-14. doi: 10.1038/nrendo.2014.236. Epub 2015 Jan 27. Review.

36.

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.

37.

A carbon nanotube-polymer composite for T-cell therapy.

Fadel TR, Sharp FA, Vudattu N, Ragheb R, Garyu J, Kim D, Hong E, Li N, Haller GL, Pfefferle LD, Justesen S, Herold KC, Fahmy TM.

Nat Nanotechnol. 2014 Aug;9(8):639-47. doi: 10.1038/nnano.2014.154. Epub 2014 Aug 3. Erratum in: Nat Nanotechnol. 2014 Sep;9(9):723. Harold, Kevin C [corrected to Herold, Kevan C].

PMID:
25086604
38.

Analysis of β-cell death in type 1 diabetes by droplet digital PCR.

Usmani-Brown S, Lebastchi J, Steck AK, Beam C, Herold KC, Ledizet M.

Endocrinology. 2014 Sep;155(9):3694-8. doi: 10.1210/en.2014-1150. Epub 2014 Jul 8.

39.

Humanized mice as a model for aberrant responses in human T cell immunotherapy.

Vudattu NK, Waldron-Lynch F, Truman LA, Deng S, Preston-Hurlburt P, Torres R, Raycroft MT, Mamula MJ, Herold KC.

J Immunol. 2014 Jul 15;193(2):587-96. doi: 10.4049/jimmunol.1302455. Epub 2014 Jun 18.

40.

Biomarkers in type 1 diabetes: application to the clinical trial setting.

Tooley JE, Herold KC.

Curr Opin Endocrinol Diabetes Obes. 2014 Aug;21(4):287-92. doi: 10.1097/MED.0000000000000076. Review.

41.

The receptor for advanced glycation end products (RAGE) affects T cell differentiation in OVA induced asthma.

Akirav EM, Henegariu O, Preston-Hurlburt P, Schmidt AM, Clynes R, Herold KC.

PLoS One. 2014 Apr 23;9(4):e95678. doi: 10.1371/journal.pone.0095678. eCollection 2014.

42.

Restoring immune balance in type 1 diabetes.

Herold KC.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):261-3. doi: 10.1016/S2213-8587(13)70123-2. Epub 2013 Sep 23. No abstract available.

PMID:
24622404
43.

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.

Diabetes Care. 2014 Apr;37(4):979-84. doi: 10.2337/dc13-2359. Epub 2014 Feb 18.

44.

Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.

Vudattu NK, Herold KC.

Expert Opin Biol Ther. 2014 Mar;14(3):377-85. doi: 10.1517/14712598.2014.881797. Review.

PMID:
24517093
45.

A humanized mouse model of autoimmune insulitis.

Viehmann Milam AA, Maher SE, Gibson JA, Lebastchi J, Wen L, Ruddle NH, Herold KC, Bothwell AL.

Diabetes. 2014 May;63(5):1712-24. doi: 10.2337/db13-1141. Epub 2014 Jan 29.

46.

Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells.

Tornovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben Haroush R, Hija A, Stolovich-Rain M, Furth-Lavi J, Granot Z, Porat S, Philipson LH, Herold KC, Bhatti TR, Stanley C, Ashcroft FM, In't Veld P, Saada A, Magnuson MA, Glaser B, Dor Y.

Cell Metab. 2014 Jan 7;19(1):109-21. doi: 10.1016/j.cmet.2013.11.007. Epub 2013 Dec 12.

47.

Delayed anti-CD3 therapy in a mouse heart transplant model induced tolerance and long-term survival of allograft: achieving tolerance.

Vudattu NK, Herold KC.

Immunotherapy. 2013 Nov;5(11):1173-6. doi: 10.2217/imt.13.113.

PMID:
24188671
48.

Characterization of residual β cell function in long-standing type 1 diabetes.

Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC.

Diabetes Metab Res Rev. 2014 Feb;30(2):154-62. doi: 10.1002/dmrr.2478.

PMID:
24115337
49.

Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.

Ghazi T, Rink L, Sherr JL, Herold KC.

Diabetes Care. 2014;37(1):210-6. doi: 10.2337/dc13-1169. Epub 2013 Aug 12.

50.

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17.

Supplemental Content

Loading ...
Support Center